Primary study · included by 1 review

Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.

Yang 2022 · Yang Yang, Tan Lijie, Hu Jian, et al. · Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.

Non-Cochrane · intervention · 2026 · cited as Yang 2022 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.